TNFRSF4 KO cell line available to order. Free of charge wild type control provided.
ACT 35, ACT35 antigen, ATC35 antigen, CD 134, CD134 antigen, IMD16, Lymphoid activation antigene ACT35, OX 40, OX40 antigen, OX40 cell surface antigen, OX40 homologue, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, TNF receptor superfamily member 4, TNFRSF 4, TNR4_HUMAN, TXGP1, Tumor necrosis factor receptor superfamily member 4, Txgp 1l
TNFRSF4 KO cell line available to order. Free of charge wild type control provided.
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control: Human wild-type HCT116 cell line (Human wild-type HCT116 cell line ab288559). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
CD134 also known as OX40 or TNFRSF4 is a receptor that plays an essential role in immune response regulation. This receptor is part of the tumor necrosis factor receptor (TNFR) superfamily and has a molecular mass of approximately 50 kDa. CD134 is expressed on activated T cells particularly CD4+ T cells and is present on various other immune cells under specific conditions. The receptor binds to the OX40L its ligand which is expressed on antigen-presenting cells such as dendritic cells and B cells.
CD134 influences T cell proliferation survival and memory formation being an important component of the immune system's adaptive response. OX40L engagement with CD134 enhances the activation and survival of T cells promoting long-term immunity. This interaction does not form part of a larger complex but functions as a direct signaling mechanism that augments T cell receptor (TCR) signaling leading to increased cytokine production and sustained immune responses essential for controlling infections and cancer.
CD134 signaling intersects with the nuclear factor-kappa B (NF-κB) and phosphoinositide 3-kinase (PI3K) pathways. These pathways play significant roles in regulating immune responses and cell survival. Through the NF-κB pathway CD134 influences gene transcription related to immune activation. It also connects with other immune regulatory proteins such as CD28 which further potentiates T cell responses and enhances effector functions.
CD134 has connections to autoimmune diseases and cancers. Overactivity of the CD134-OX40L pathway can lead to exacerbated autoimmune conditions such as lupus. This receptor has also been implicated in tumor immunity where its activation enhances the anti-tumor response of T cells. CD134 interacts with CTLA-4 another immune checkpoint protein playing a role in balancing immune activation and regulation within these disease contexts.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com